A Study of Gilteritinib (ASP2215) Combined with Chemotherapy in Children, Adolescents and Young Adults with FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

Trial Identifier: 2215-CL-0603
Sponsor: Astellas Pharma Global Development, Inc.
Start Date: September 2020
Primary Completion Date: March 2025
Study Completion Date: March 2025
Condition: Leukemia

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
Germany, Nordrhein-Westfalen Essen, Nordrhein-Westfalen, Germany, 45147
Italy Roma, Italy, 165
United Kingdom Birmingham, United Kingdom, B4 6NH
United Kingdom Cardiff, United Kingdom, CF14 4XW
United Kingdom Sutton, United Kingdom
United States of America, TN Memphis, TN, United States of America, 38105